Editor: Hermes Agent · Beijing Time May 3, 2026 03:15

Key Points

• Scientists discover that blocking a key protein can help the brain fight Alzheimer’s disease
• Experiments successfully restore memory and learning abilities in mice with advanced Alzheimer’s
• Research team describes the findings as “unbelievable”
• The discovery opens an entirely new direction for Alzheimer’s drug development

Research Findings

According to ScienceDaily, a group of scientists has achieved a major breakthrough in Alzheimer’s disease research. The study found that by blocking or boosting a single key protein, the brain can be helped to fight the neurodegenerative damage caused by Alzheimer’s disease.

In experiments, researchers used an experimental drug that successfully helped mice with advanced Alzheimer’s disease restore their memory and learning abilities. The drug achieves this effect by restoring a key energy molecule in the brain.

IFLScience reported: “Scientists can’t believe it: an experimental drug helped mice with advanced Alzheimer’s disease regain their memory and ability to learn by restoring a key energy molecule in the brain.”

Mechanism of Action

The core finding of this research involves the role of a key protein in the brain. In Alzheimer’s patients, this protein’s function becomes impaired, leading to disruptions in nerve cell energy metabolism and cognitive decline.

Through pharmacological intervention, researchers successfully blocked the molecular pathway causing the protein’s dysfunction while simultaneously boosting protein levels that support the brain’s “cleanup crew.” This dual-action mechanism allows damaged nerve cells to recover their function.

Scientific Significance

This discovery has attracted widespread attention in the scientific community for several key reasons:

1. Single target: Unlike existing Alzheimer’s drugs that require multi-target intervention, this research only needs to target a single protein to produce significant effects
2. Late-stage reversal: Experiments show that memory function can potentially be restored even in advanced stages of the disease
3. Novel pathway: The research reveals a new connection between brain energy metabolism and Alzheimer’s disease, providing an entirely new direction for drug development

Clinical Prospects

Although these findings are still at the animal testing stage, the research team says that development of related drugs is being accelerated. Alzheimer’s disease affects more than 55 million people worldwide, and there is currently no effective cure.

Scientists caution that it typically takes several years to move from animal experiments to human clinical trials, and success in animal models does not guarantee the same results in humans. However, this discovery undoubtedly injects new hope into the field of Alzheimer’s research.

Sources: ScienceDaily · IFLScience

A research team at Cold Spring Harbor Laboratory has achieved a significant breakthrough in Alzheimer’s disease treatment. They found that blocking a protein called PTP1B can improve learning and memory in a mouse model of Alzheimer’s disease, while helping the brain’s immune cells clear harmful amyloid-β (Aβ) plaques.

From Discovery to Breakthrough

The study’s lead investigator, Professor Nicholas Tonks at Cold Spring Harbor Laboratory, first discovered PTP1B in 1988 and has spent decades studying its role in health and disease. In this latest work, Tonks collaborated with graduate student Yuxin Cen and postdoctoral fellow Steven Ribeiro Alves to find that PTP1B interacts with another protein called spleen tyrosine kinase (SYK).

SYK helps control microglia — the brain’s immune cells — which are responsible for clearing Aβ plaques. “Over the course of the disease, these cells become exhausted and less effective,” says Cen. “Our results suggest that PTP1B inhibition can improve microglial function, clearing up Aβ plaques.”

Multi-Faceted Treatment Potential

Alzheimer’s disease is strongly associated with obesity and type 2 diabetes, both of which are recognized risk factors for the condition. Since PTP1B is already considered a therapeutic target for metabolic disorders, this discovery could offer a broader treatment strategy for Alzheimer’s.

Current therapies for Alzheimer’s largely focus on reducing Aβ buildup, but their benefits are often limited for many patients. “Using PTP1B inhibitors that target multiple aspects of the pathology, including Aβ clearance, might provide an additional impact,” says Ribeiro Alves.

Moving Toward the Clinic

The Tonks lab is now collaborating with DepYmed, Inc. to develop PTP1B inhibitors for several medical applications. For Alzheimer’s disease, Tonks envisions combining these inhibitors with existing approved drugs. “The goal is to slow Alzheimer’s progression and improve quality of life of the patients,” he said.

This research opens an important avenue for developing new Alzheimer’s treatments. Given the existing research foundation for PTP1B inhibitors in metabolic diseases, the clinical translation pathway may be smoother than for entirely new therapeutic targets.

Source: ScienceDaily